18th Jul 2025
Telehealth has rapidly evolved from a niche offering into a mainstream pillar of healthcare delivery. Driven by technological advances and the global pandemic, virtual care services have expanded at an unprecedented pace, reshaping how patients and providers interact. This article examines the transformation of telehealth with a spotlight on Hims & Hers Health (NYSE: HIMS) – a direct-to-consumer telehealth innovator – and its role in the digital healthcare revolution.
Telehealth’s Market Outlook and Financial Trajectory
Telehealth usage grew rapidly during the COVID-19 pandemic and continues to expand. According to McKinsey, consumer adoption jumped from only about 11% of U.S. consumers using telehealth in 2019 to roughly 46% by 2020 as in-person visits were canceled. McKinsey estimates that up to $250 billion of U.S. healthcare spending could be delivered virtually in the post-pandemic landscape.
Industry projections forecast significant growth for the telehealth market. The global telehealth market was valued at approximately $101 billion in 2023 and is expected to maintain a 20–25% compound annual growth rate (CAGR) through the decade. Fortune Business Insights forecasts the market will grow from about $186 billion in 2025 to over $790 billion by 2032, a ~22.9% CAGR.
Hims & Hers Health: Financial Performance and Growth Strategy
Founded in 2017, Hims & Hers Health has emerged as a notable telehealth disruptor with impressive financial metrics. The company’s revenue has grown at a blistering pace over the past few years. In 2022, Hims & Hers reported $526.9 million in full-year revenue, up 94% year-over-year. This trajectory continued with full-year 2023 revenue reaching $872.0 million (approximately 65% growth from 2022), and by 2024, revenue had leaped to $1.48 billion, a 69% increase year-over-year, according to their investor reports.
Notably, Hims & Hers achieved significant profitability milestones in 2024, reporting a net income of $126.0 million for the full year, compared to a net loss of $(23.5) million in 2023. The company’s subscriber base expanded to over 2.2 million by the end of 2024, up 45% from the prior year.
In 2023, Hims & Hers began offering access to popular GLP-1 weight-loss medications and projects continued growth in this area. Their revenue, excluding the GLP-1 weight loss offering, increased 43% year-over-year to over $1.2 billion in 2024, indicating strong performance across their core business segments. The company also continues to maintain strong gross margins of 79% for the full year 2024.
Competitive Market Position
In comparison, industry pioneer Teladoc Health generated $2.57 billion in revenue in 2024, according to their financial releases, but saw a 1% year-over-year decline and reported a $1.0 billion net loss. While Teladoc maintains a larger member base (approximately 90 million members), Hims & Hers’ direct-to-consumer model has delivered superior gross margins (79% versus Teladoc’s 70%) and stronger growth momentum. This differentiated approach of selling proprietary products and subscriptions appears to provide Hims & Hers with inherent profitability advantages as it continues to scale.
Investment Considerations in Digital Health
The digital health and telehealth sector presents enticing growth prospects along with notable risks. Investors interested in this space have multiple avenues to gain exposure:
Individual Telehealth Stocks
Buying shares of a company like Hims & Hers Health offers direct exposure to the growth and performance of that specific business. The upside is significant if the company executes well – capturing market share, growing revenue, and achieving profitability. For example, HIMS has delivered high double-digit revenue growth, and investors bullish on its model might seek to capitalize on its momentum.
However, single-stock exposure comes with company-specific risk. Any stumble or unexpected bad news can hurt the stock price sharply. Hims & Hers’ recent volatility is a case in point: when uncertainty arose about its weight-loss drug offerings, the stock plunged over 20% in a day, as Reuters reported.
Investors in individual telehealth stocks need conviction in that company’s competitive edge and must be comfortable with potentially high volatility. Thorough due diligence on financial health, management strategy, and industry trends is crucial before making direct investments in telehealth companies.
Leveraged ETF Strategies for Telehealth Exposure
For investors with high risk tolerance looking to amplify their bets on telehealth companies, leveraged ETF options have emerged in the market. New 2X leveraged single-stock ETFs offer traders a way to seek enhanced daily returns on companies like Hims & Hers without requiring a margin account.
These innovative leveraged telehealth ETF options seek daily investment results that correspond to twice (200%) the daily return of their underlying stocks. For instance, a 2X leveraged ETF based on HIMS would aim to deliver twice the daily percentage change of Hims & Hers stock.
However, it’s crucial to understand that these products reset daily, meaning they’re designed specifically for short-term trading rather than long-term holding. Due to the mathematics of daily compounding, over periods longer than a single day, a leveraged ETF may perform quite differently than simply doubling the underlying stock’s return.
These funds carry substantial risks and are generally not suitable for buy-and-hold investors who may not closely monitor their holdings. They’re designed for knowledgeable traders who understand leveraged investment objectives, recognize the risks of seeking double exposure, and are willing to actively manage their positions – potentially even daily.
Final Thoughts
The transformation of telehealth represents a substantial investment opportunity, with the market projected to grow from approximately $186 billion in 2025 to over $790 billion by 2032. Companies like Hims & Hers Health demonstrate the financial potential, with significant revenue growth and improving profitability metrics.
For investors, the telehealth sector offers multiple entry points – from direct stock investments to leveraged ETF strategies for those seeking amplified exposure. While volatility should be expected, telehealth’s integration into mainstream healthcare suggests long-term staying power for well-positioned companies.
Disclosures:
The information, analysis, and opinions expressed herein are for general information only.
Nothing contained herein is intended to constitute legal, tax, securities, or investment advice,
nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type.
Past performance is not indicative of future results.
